BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25618179)

  • 1. The expanding role of co-trimoxazole in developing countries.
    Church JA; Fitzgerald F; Walker AS; Gibb DM; Prendergast AJ
    Lancet Infect Dis; 2015 Mar; 15(3):327-39. PubMed ID: 25618179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-trimoxazole prophylaxis for children who are HIV-exposed and uninfected: a systematic review.
    Wedderburn CJ; Evans C; Slogrove AL; Rehman AM; Gibb DM; Prendergast AJ; Penazzato M
    J Int AIDS Soc; 2023 Jun; 26(6):e26079. PubMed ID: 37292018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa.
    Bwakura-Dangarembizi M; Kendall L; Bakeera-Kitaka S; Nahirya-Ntege P; Keishanyu R; Nathoo K; Spyer MJ; Kekitiinwa A; Lutaakome J; Mhute T; Kasirye P; Munderi P; Musiime V; Gibb DM; Walker AS; Prendergast AJ
    N Engl J Med; 2014 Jan; 370(1):41-53. PubMed ID: 24382064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scaling-up co-trimoxazole prophylaxis in HIV-exposed and HIV-infected children in high HIV-prevalence countries.
    Zachariah R; Harries AD; Luo C; Bachman G; Graham SM
    Lancet Infect Dis; 2007 Oct; 7(10):686-93. PubMed ID: 17897611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis.
    Suthar AB; Vitoria MA; Nagata JM; Anglaret X; Mbori-Ngacha D; Sued O; Kaplan JE; Doherty MC
    Lancet HIV; 2015 Apr; 2(4):e137-50. PubMed ID: 26424674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of co-trimoxazole for urinary tract infections in developing countries.
    Leblebicioglu H; Ozaras R; Sunbul M
    Lancet Infect Dis; 2015 Jul; 15(7):764-5. PubMed ID: 26122444
    [No Abstract]   [Full Text] [Related]  

  • 7. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.
    Walker AS; Ford D; Gilks CF; Munderi P; Ssali F; Reid A; Katabira E; Grosskurth H; Mugyenyi P; Hakim J; Darbyshire JH; Gibb DM; Babiker AG
    Lancet; 2010 Apr; 375(9722):1278-86. PubMed ID: 20347483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Level of understanding of co-trimoxazole use among HIV infected, recurrent pulmonary tuberculosis suspects at a national referral tuberculosis clinic in Kampala, Uganda: a qualitative analysis.
    Okwera A; Mafigiri DK; Guwatudde D; Whalen C; Joloba M
    Afr Health Sci; 2015 Mar; 15(1):49-57. PubMed ID: 25834530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial.
    Sandison TG; Homsy J; Arinaitwe E; Wanzira H; Kakuru A; Bigira V; Kalamya J; Vora N; Kublin J; Kamya MR; Dorsey G; Tappero JW
    BMJ; 2011 Mar; 342():d1617. PubMed ID: 21454456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations.
    Badri M; Ehrlich R; Wood R; Maartens G
    AIDS; 2001 Jun; 15(9):1143-8. PubMed ID: 11416716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis.
    Yazdanpanah Y; Losina E; Anglaret X; Goldie SJ; Walensky RP; Weinstein MC; Toure S; Smith HE; Kaplan JE; Freedberg KA;
    AIDS; 2005 Aug; 19(12):1299-308. PubMed ID: 16052085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda.
    Mermin J; Lule J; Ekwaru JP; Malamba S; Downing R; Ransom R; Kaharuza F; Culver D; Kizito F; Bunnell R; Kigozi A; Nakanjako D; Wafula W; Quick R
    Lancet; 2004 Oct 16-22; 364(9443):1428-34. PubMed ID: 15488218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of co-trimoxazole prophylaxis on morbidity and mortality of HIV-exposed, HIV-uninfected infants in South Africa: a randomised controlled, non-inferiority trial.
    Daniels B; Coutsoudis A; Moodley-Govender E; Mulol H; Spooner E; Kiepiela P; Reddy S; Zako L; Ho NT; Kuhn L; Ramjee G
    Lancet Glob Health; 2019 Dec; 7(12):e1717-e1727. PubMed ID: 31708152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study.
    Mermin J; Ekwaru JP; Liechty CA; Were W; Downing R; Ransom R; Weidle P; Lule J; Coutinho A; Solberg P
    Lancet; 2006 Apr; 367(9518):1256-61. PubMed ID: 16631881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revisiting Co-trimoxazole Prophylaxis for African Adults in the Era of Antiretroviral Therapy: A Randomized Controlled Clinical Trial.
    Laurens MB; Mungwira RG; Nampota N; Nyirenda OM; Divala TH; Kanjala M; Mkandawire FA; Galileya LT; Nyangulu W; Mwinjiwa E; Downs M; Tillman A; Taylor TE; Mallewa J; Plowe CV; van Oosterhout JJ; Laufer MK
    Clin Infect Dis; 2021 Sep; 73(6):1058-1065. PubMed ID: 33744963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of malaria and anaemia among HIV infected pregnant women receiving co-trimoxazole prophylaxis in Tanzania: a cross sectional study in Kinondoni Municipality.
    Manyanga VP; Minzi O; Ngasala B
    BMC Pharmacol Toxicol; 2014 Apr; 15():24. PubMed ID: 24761799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy.
    Crook AM; Turkova A; Musiime V; Bwakura-Dangarembizi M; Bakeera-Kitaka S; Nahirya-Ntege P; Thomason M; Mugyenyi P; Musoke P; Kekitiinwa A; Munderi P; Nathoo K; Prendergast AJ; Walker AS; Gibb DM;
    BMC Med; 2016 Mar; 14():50. PubMed ID: 27004529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective efficacy of prolonged co-trimoxazole prophylaxis in HIV-exposed children up to age 4 years for the prevention of malaria in Uganda: a randomised controlled open-label trial.
    Homsy J; Dorsey G; Arinaitwe E; Wanzira H; Kakuru A; Bigira V; Muhindo M; Kamya MR; Sandison TG; Tappero JW
    Lancet Glob Health; 2014 Dec; 2(12):e727-36. PubMed ID: 25433628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of early chemoprophylaxis with co-trimoxazole on nutritional status evolution in HIV-1-infected adults in Abidjan, Côte d'Ivoire.
    Castetbon K; Anglaret X; Attia A; Toure S; Dakoury-Dogbo N; Messou E; N'Dri-Yoman T; Dabis F; Salamon R;
    AIDS; 2001 May; 15(7):869-76. PubMed ID: 11399959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome from treatment of Pneumocystis jirovecii pneumonia with co-trimoxazole.
    Fisk M; Sage EK; Edwards SG; Cartledge JD; Miller RF
    Int J STD AIDS; 2009 Sep; 20(9):652-3. PubMed ID: 19710343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.